REDWOOD CITY, Calif.--Biopharmacauetical company Genelabs Technologies will receive $4.8 million to fund its second year of genomics-based research for the US Defense Advanced Research Projects Agency, the research arm of the US Department of Defense. The funding is a 25 percent increase over what Genelabs received in 1998 under the agency's Unconventional Pathogen Countermeasures Program. Genelabs will use the money to apply its platform technologies, which create drugs that function by binding to DNA or double-stranded RNA, to develop pharmaceutical countermeasures to biological warfare agents.
DOE Gives Genelabs $4.8M For Pathogens Research
Feb 12, 1999